Search

Your search keyword '"Raychaudhuri, Jyoti"' showing total 6 results
Start Over Author "Raychaudhuri, Jyoti"
6 results on '"Raychaudhuri, Jyoti"'

2. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma

Author

Nishihori, Taiga, Alekshun, Todd J., Shain, Kenneth, Sullivan, Daniel M., Baz, Rachid, Perez, Lia, Pidala, Joseph, Kharfan-Dabaja, Mohamed A., Ochoa-Bayona, Jose L., Fernandez, Hugo F., Yarde, Danielle N., Oliveira, Vasco, Fulp, William, Han, Gang, Kim, Jongphil, Chen, Dung-Tsa, Raychaudhuri, Jyoti, Dalton, William, Anasetti, Claudio, and Alsina, Melissa

Published
2012
Full Text
View/download PDF

3. Allogeneic Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) after Pretransplant 5-Azacitidine.

Author

Field, Teresa, primary, Alsina, Melissa, additional, Ayala, Ernesto, additional, Fernandez, Hugo, additional, Janssen, William, additional, Karfan-Dabaja, Mohammed, additional, Lancet, Jeffery, additional, Melchert, Mafda, additional, Raychaudhuri, Jyoti, additional, Sullivan, Daniel, additional, List, Alan, additional, Anasetti, Claudio, additional, Poling, William, additional, and Perkins, Janelle, additional

Published
2007
Full Text
View/download PDF

4. Phase I/II Trial of High-Dose Melphalan (M) and Topotecan (T) Followed by Autologous Stem Cell Rescue in Patients ≤ 60 and > 60 Years of Age with Multiple Myeloma (MM).

Author

Sullivan, Daniel, primary, Alsina, Melissa, additional, Anasetti, Claudio, additional, Field, Teresa, additional, Kharfan-Dabaja, Mohamed, additional, Fernandez, Hugo, additional, Dalton, William, additional, Ayala, Ernesto, additional, Raychaudhuri, Jyoti, additional, Perez, Lia, additional, Perkins, Janelle, additional, Schell, Michael, additional, McIsaac, Christine, additional, Maddox, Beth, additional, Gump, Jana, additional, Lush, Richard, additional, and Frudakis, Tony, additional

Published
2007
Full Text
View/download PDF

5. Phase I Study of Bortezomib, (BTZ) Followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL).

Author

Alekshun, Todd, primary, Mcisaac-Simonelli, Christine, additional, Kharfan-Dabaja, Mohamed, additional, Dalton, William, additional, Djulbegovic, Benjamin, additional, Fernandez, Hugo, additional, Sullivan, Daniel M., additional, Ayala, Ernesto, additional, Field, Teresa L., additional, Garrett, Dawn, additional, Janssen, William E., additional, Maddox, Beth, additional, Perez, Lia, additional, Kettner, Dawn, additional, Perkins, Janelle, additional, Raychaudhuri, Jyoti, additional, Anasetii, Claudio, additional, and Alsina, Melissa, additional

Published
2007
Full Text
View/download PDF

6. Bortezomib salvage followed by a Phase I/ II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma.

Author

Nishihori, Taiga, Alekshun, Todd J., Shain, Kenneth, Sullivan, Daniel M., Baz, Rachid, Perez, Lia, Pidala, Joseph, Kharfan-Dabaja, Mohamed A., Ochoa-Bayona, Jose L., Fernandez, Hugo F., Yarde, Danielle N., Oliveira, Vasco, Fulp, William, Han, Gang, Kim, Jongphil, Chen, Dung-Tsa, Raychaudhuri, Jyoti, Dalton, William, Anasetti, Claudio, and Alsina, Melissa

Subjects
KARYOTYPES, CHROMOSOME abnormalities, STATISTICAL hypothesis testing, MULTIPLE myeloma, MESSENGER RNA, STEM cells
Abstract

We conducted a Phase 1/2 study of bortezomib administered in combination with high-dose melphalan followed by tandem autologous transplants in patients with primary resistant multiple myeloma. Thirty patients received two cycles of salvage bortezomib followed by stem cell mobilization with granulocyte colony-stimulating factor and harvest. Melphalan 100 mg/m2 per day on two consecutive days was administered, immediately followed by one dose of bortezomib (dose escalation) and stem cell infusion. The median beta 2-microglobulin was 4·35 mg/l (range: 1·8-11·4); albumin was 37 g/l (range: 3·1-4·9); high-risk karyotypes were noted in 45% of patients. The maximum planned dose of bortezomib at 1·3 mg/m2 was well tolerated and a formal maximum tolerated dose was not determined. The peak of best overall response (≥partial response) and complete response rates after tandem transplants were 84% and 36%, respectively. With a median follow-up of 48 months, the median progression-free survival was 15 [95% confidence interval ( CI): 11-21] months and the median overall survival was 35 (95% CI: 22-43) months. Correlative studies demonstrated decreased expression of BRCA2 ( P = 0·0072) and FANCF ( P = 0·0458) mRNA following bortezomib treatment. Bortezomib combined with high-dose melphalan is a well-tolerated conditioning with some activity in patients with resistant myeloma. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results